Fierce Biotech10d
ALX lays off 30% of staff to pay for more trials of CD47 blocker
ALX Oncology is laying off 30% of its workforce as the biotech seeks to channel its cash into further trials of its CD47 ...
Bay Area biotech firm once worth more than $4B lays off 30% of staff
ALX Oncology is laying off 30% of its staff, mainly in preclinical research, to redirect money toward clinical trials, ...
Business Insider10d
ALX Oncology will highlight progress across its clinical pipeline
ALX Oncology (ALXO) will highlight progress across its clinical pipeline, including continued advancement of investigational CD47-blocker evorpacept and planned entry into the clinic of its novel ...
Nasdaq1mon
ALX Oncology Presents Positive Evorpacept Data at 2025 ASCO Gastrointestinal Cancers Symposium, Highlighting Strong Efficacy in HER2-Positive Cancer
ALX Oncology announced promising results from the ASPEN-06 Phase 2 clinical trial of its CD47-blocker, evorpacept, at the 2025 ASCO Gastrointestinal Cancers Symposium. This investigational ...